Due to the complexity of tumor biology, tumor drug development is full of challenges. Compared with other diseases, Hematological malignancies require multi-omics platforms (M: morphology, I: immunology, C: cytogenetics, M: molecular biology, etc.) to provide necessary information for disease diagnosis, treatment, prognosis, etc., and rely on the services provided by the central laboratory. KingMyLab has established a sound MICM and other multi-omics platforms, which can fully support the research of biomarkers related to Hematological malignancies drug development. At present, we have helped more than 300 clinical research projects of Hematological malignancies , involving small molecules, monoclonal antibody/double antibody and other macromolecules, CAR-T (chimeric antigen receptor T cell) and other therapies, covering diseases such as leukemia, lymphoma and multiple myeloma.

Due to the complexity of tumor biology, tumor drug development is full of challenges. Compared with other diseases, Hematological malignancies require multi-omics platforms (M: morphology, I: immunology, C: cytogenetics, M: molecular biology, etc.) to provide necessary information for disease diagnosis, treatment, prognosis, etc., and rely on the services provided by the central laboratory. KingMyLab has established a sound MICM and other multi-omics platforms, which can fully support the research of biomarkers related to Hematological malignancies drug development. At present, we have helped more than 300 clinical research projects of Hematological malignancies , involving small molecules, monoclonal antibody/double antibody and other macromolecules, CAR-T (chimeric antigen receptor T cell) and other therapies, covering diseases such as leukemia, lymphoma and multiple myeloma.

Due to the complexity of tumor biology, tumor drug development is full of challenges. Compared with other diseases, Hematological malignancies require multi-omics platforms (M: morphology, I: immunology, C: cytogenetics, M: molecular biology, etc.) to provide necessary information for disease diagnosis, treatment, prognosis, etc., and rely on the services provided by the central laboratory. KingMyLab has established a sound MICM and other multi-omics platforms, which can fully support the research of biomarkers related to Hematological malignancies drug development. At present, we have helped more than 300 clinical research projects of Hematological malignancies , involving small molecules, monoclonal antibody/double antibody and other macromolecules, CAR-T (chimeric antigen receptor T cell) and other therapies, covering diseases such as leukemia, lymphoma and multiple myeloma.